General Approach to, and Perspectives on Clinical Research in, Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Seminars in Hematology

Volumn 43, Issue 2, 2006, Pages 89-95

  Estey, Elihu H ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CLOFARABINE; CLORETAZINE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; GEMTUZUMAB OZOGAMICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; IDARUBICIN; MITOXANTRONE; TIPIFARNIB; UNCLASSIFIED DRUG; VALSPODAR;

ACUTE GRANULOCYTIC LEUKEMIA; AGING; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL RESEARCH; CONTINUOUS INFUSION; CYTOGENETICS; DEATH; DRUG CYTOTOXICITY; DRUG FATALITY; FEASIBILITY STUDY; FUNCTIONAL ASSESSMENT; GROUPS BY AGE; HIGH RISK POPULATION; HUMAN; INFORMATION RETRIEVAL; KARYOTYPE; LOW DRUG DOSE; MEDICAL INFORMATION; ORGAN; PERFORMANCE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RISK; SURVIVAL TIME; THERAPY DELAY; TREATMENT FAILURE; TREATMENT RESPONSE;

ACUTE DISEASE; AGED; CLINICAL TRIALS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID; MIDDLE AGED; THERAPEUTIC HUMAN EXPERIMENTATION;

EID: 33646015039     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2006.01.002     Document Type: Article

References (30)

1. Rowe J.M., Neuberg D., Friedenberg W., Bennett J.M., Paietta E., Makary A.Z., et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with AML. A trial by the Eastern Cooperative Oncology Group. Blood 103 (2004) 479-485
2. Goldstone A.H., Burnett A.K., Wheatley K., Smith A.G., Hutchinson R.M., and Clark R.E. Attempts to improve treatment outcomes in AML in older patients. The results of the United Kingdom Medical Research Council AML11 trial. Blood 98 (2001) 1302-1311
3. Anderson J.E., Kopecky K.J., Willman C.L., Head D., O'Donnell M.R., Luthardt F.W., et al., A Southwest Oncology Group Study. Outcome after induction chemotherapy for older patients with AML is not improved with mitoxantrone and etoposide compared to daunorubicin and cytarabine. Blood 100 (2002) 3869-3876
4. Van der Holt B., Loewenberg B., Burnett A.K., Knauff W.U., Sheperd J., Paolo P., et al. The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated AML in relation to MDR1 status at diagnosis. Blood 106 (2005) 2646-2654
5. Estey E.H., Thall P.F., Giles F.G., Wang X.-M., Cortes J.E., Beran M., et al. Gemtuzumab ozogamycin with or without interleukin 11 in patients 65 years of age or older with untreated AML or high-risk MDS. Comparison with idarubicin plus high-dose continuous infusion cytosine arabinoside. Blood 99 (2002) 4343-4349
6. Kahn S.B., Begg C.B., Mazza J.J., Bennett J.M., Bonner H., and Glick J.H. Full dose vs. attenuated dose daunorubicin, cytosine arabinoside and 6-thioguanine in the treatment of acute non-lymphocytic leukemia in the elderly. J Clin Oncol 2 (1984) 865-870
7. Simon R. Importance of prognostic factors in cancer clinical trials. Cancer Treat Rep 68 (1984) 185-192
8. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al. The predictive value of hierarchical cytogenetic classification in older adults with AML:analysis of 1,065 patients entered into the MRC AML 11 trial. Blood 98 (2001) 1312-1320
9. Estey E., Thall P., Beran M., Kantarjian H., Pierce S., and Keating M. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or AML) on outcome of AML-type chemotherapy. Blood 90 (1997) 2969-2977
10. Goldstone A.H., Burnett A.K., Avivi I., Hills R., and Wheatley K. Secondary AML has a worse outcome than de novo AML even taking into account cytogenetics and age. AML 10,11,12 MRC trials. Blood 100 (2002) 88a abstr
11. National Comprehensive Cancer Network (NCCN) AML Panel. AML clinical practice guidelines. J Natl Compr Cancer Network 1 (2003) 520-539
12. Baer M.R., George S.L., Dodge R.K., O'Laughlin K.L., Minderman H., Caligiuri M., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia. Cancer and Leukemia Group B study 9720. Blood 100 (2002) 1224-1232
13. Giralt S., Estey E., Albitar M., van Besien K., Rhondon G., Anderlini P., et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy. Harnessing graft- versus-leukemia without myeloablative therapy. Blood 89 (1997) 4531-4536
14. Alyea E.P., Kim H.T., Ho V., Cutler C., Gribben J., DeAngelo D.J., et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood 105 (2005) 1810-1814
15. Burnett A.K., Wheatley K., Stevens R., Goldstone A.H., Hann I., Prentice A.G., et al. Further data to question the use of allo bone marrow transplant in AML 1st remission in addition to intensive chemotherapy. The MRC experience in 715 patients under age 44 years with donors available. Blood 100 (2002) 74a abstr
16. Burnett A.K., Goldstone A.H., Stevens R., Hann I.M., Rees J.K., and Wheatley K. Biologic characteristics determine the outcome of allogeneic or autologous BMT in AML CR1. Blood 86 (1995) 614a abstr
17. Kottaridis P.D., Gale R.E., Holt M.P., Wheatley K., Goldstone A.H., Burnett A.K., et al. Consolidation of AML therapy with autograft and allograft procedures does not negate the poor prognostic impact of flt3 internal tandem duplications-results from the UK MRC 10 and 12 trials. Blood 100 (2002) 75a abstr
18. Tibes R., de Lima M., Estey E., Shahjahan R., and Champlin R. Non-myeloablative HSCT in elderly AML/MDS patients in 1st CR. Proc Am Soc Clin Oncol (2005) abstr 6655
19. Lowenberg B., Zittoun R., Kerkhofs H., Jehn U., Abels J., Debusscher L., et al. On the value of intensive remission induction therapy in elderly patients of 65+ years with AML. A randomized phase III study of the European Organization for Research and Treatment of Cancer Group. J Clin Oncol 7 (1989) 1268-1274
20. Burnett A.K., Milligan D., Prentice A.G., Goldstone A.W., McMullin M.F., Wheatley K., et al. Low dose ara-C versus hydroxyurea with or without retinoid in older patients not considered fit for intensive chemotherapy. The UK NCRI AML14 trial. Blood 104 (2002) 872 abstr
21. Tilly H., Castaigne S., Bordessoule D., Casassus P., LePrise P.Y., Tertain G., et al. Low dose cytarabine vs. intensive chemotherapy in the treatment of acute nonlymphocytic leukemia in the elderly. J Clin Oncol 8 (1990) 272-279
22. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., et al. Frequency of prolonged remission after high-dose cytarabine intensification in AML varies by cytogenetic subtype. Cancer Res 58 (1998) 4173-4179
23. Sekeres M.A., Stone R.M., Zahrieh D., Morrison V., DeAngelo D.J., Galinsky I., et al. Decision-making and quality of life in older adults with AML or advanced MDS. Leukemia 18 (2004) 809-816
24. Lancet J.E., Gojo I., Gotlib J., Greer J., Kaufmann S.H., Liesveld J.L., et al. Tipifarnib in previously untreated poor-risk AML and MDS. Interim results of a phase II trial. Blood 102 (2003) 176a abstr
25. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., et al. Patients with AML and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105 (2005) 54-60
26. Bishop J.F., Matthews J.P., Young G.A., Bradstock K., and Lowenthal R.M. Intensified induction chemotherapy with high dose cytarabine and etoposide for acute myeloid leukemia. A review and updated results of the Australian Leukemia Study Group. Leuk Lymphoma 28 (1998) 315-327
27. Estey E., Wang X.-M., Thall P., Pierce S., Koller C., Faderl S., et al. Plausibility of delaying induction therapy in untreated AML. Blood 104 (2004) 879 abstr
28. Sievers E.L., Larson R.A., Stadtmauer E.A., Estey E., Loweneberg B., Dombret H., et al. Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive AML in first relapse. J Clin Oncol 19 (2001) 3244-3254
29. de Lima M., Strom S., Keating M., Kantarjian H., Pierce S., O'Brien S., et al. Implications of potential cure in AML. Development of subsequent cancer and return to work. Blood 90 (1997) 4719-4724
30. Estey E. Clinical trials in AML of the elderly. Should we change our methodology?. Leukemia 18 (2004) 1772-1774